Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768148 | 1.00 | HTR1A (0.34) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL9739360 | 0.88 | — | — | |
| SCHEMBL3308565 | 0.79 | PABPC1 (0.42) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL14272690 | 0.79 | — | — | |
| SCHEMBL10265045 | 0.79 | — | — | |
| SCHEMBL12662822 | 0.79 | — | — | |
| SCHEMBL3305308 | 0.77 | PABPC1 (0.44) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL12944468 | 0.77 | PABPC1 (0.44) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL12944477 | 0.77 | PABPC1 (0.44) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1768196 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-02-16 | — | — | US | disclosed |
| US-9708339-B2 | 1,3-benzothiazinone, sulfoxide, and sulfone compounds with electrophilic substituent | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017049321-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | MILLER MARVIN J (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-2380886-A1 | Process for the preparation of 2-aminosubstituted 1,3-benzothiazine-4-ones | Makarov Vadim A. (RU) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | HTR1A 4086/4885ADRA1D 3751/4885ADRA1A 3061/4885 |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | HTR1A 4086/4885ADRA1D 3751/4885ADRA1A 3061/4885 |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | BET1, BRD4, BRD3 | HTR1A 4086/4885ADRA1D 3751/4885ADRA1A 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.